|
Hemato-oncology / Original Article
Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing
Min Ji Jeon, Eun Sang Yu, Chul Won Choi, Dae Sik Kim
Korean J Intern Med. 2023;38(6):893-902. Published online August 21, 2023
Background/Aims: Although rituximab, an antiCD20 monoclonal antibody, has dramatically improved the clinical outcomes of diffuse large B-cell lymphoma, rituximab resistance remains a challenge.
Methods: We developed a rituximab-resistant cell line (RRCL) by sequential exposure to gradually increasi..
|
|
|
Hemato-oncology / Original Article
How myeloproliferative neoplasms patients’ experience and expectations differ from physicians’: the international MPN Landmark survey
Ja Min Byun, Soo-Mee Bang, Eun-Ji Choi, Ki-Seong Eom, Chul Won Jung, Hye-seon Kim, Jiwon Park, Chul Won Choi
Korean J Intern Med. 2022;37(2):444-454. Published online February 28, 2022
Background/Aims: Recent advances in the understanding of the pathophysiology of myeloproliferative neoplasms (MPN) were not paralleled with advances in treatment options; thus many questions regarding optimal MPN management remain unanswered. Here, we report the results of descriptive survey study o..
|
|
|
Hemato-oncology / Original Article
Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
Yoo Jin Na, Eun Sang Yu, Dae Sik Kim, Dae-Hee Lee, Sang Cheul Oh, Chul Won Choi
Korean J Intern Med. 2021;36(Suppl 1):S196-S206. Published online April 3, 2020
Background/Aims: Nilotinib is used for treating patients with imatinib-sensitive or -resistant chronic myeloid leukemia (CML); however, nilotinib-resistant cases have been observed in recent years. In addition, a considerable number of patients receiving nilotinib developed diabetes. Metformin is a ..
|
|
|
Hemato-oncology / Original Article
The effect of the response to the coronavirus disease pandemic on treatment outcomes in patients with lymphoma and multiple myeloma
Ka-Won Kang, Byung-Hyun Lee, Min Ji Jeon, Eun Sang Yu, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Chul Won Choi, Yong Park, Byung Soo Kim
Korean J Intern Med. 2021;36(6):1459-1470. Published online October 21, 2021
Background/Aims: Relatively little data are available on how the response to the coronavirus disease 2019 (COVID-19) pandemic has affected treatment outcomes in patients receiving chemotherapy for lymphoma or multiple myeloma. We aimed to determine the effect of COVID-19 countermeasures on treatment..
|
|
|
Review
Hepatic sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic cell transplantation: historical and current considerations in Korea
Jae-Ho Yoon, Chul Won Choi, Jong-Ho Won
Korean J Intern Med. 2021;36(6):1261-1280. Published online September 24, 2021
Hepatic sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is a rare but severe complication of hematopoietic cell transplantation (HCT) showing high mortality. Multiple risk factors for SOS/VOD were identified, but it is often confused with other hepatic complications due to nonspecif..
|
|
|
Review
The 2020 revision of the guidelines for the management of myeloproliferative neoplasms
Sung-Yong Kim, Sung Hwa Bae, Soo-Mee Bang, Ki-Seong Eom, Junshik Hong, Seongsoo Jang, Chul Won Jung, Hee-Jin Kim, Ho Young Kim, Min Kyoung Kim, Soo-Jeong Kim, Yeung-Chul Mun, Seung-Hyun Nam, Jinny Park, Jong-Ho Won, Chul Won Choi
Korean J Intern Med. 2021;36(1):45-62. Published online December 4, 2020
In 2016, the World Health Organization revised the diagnostic criteria for myeloproliferative neoplasms (MPNs) based on the discovery of disease-driving genetic aberrations and extensive analysis of the clinical characteristics of patients with MPNs. Recent studies have suggested that additional som..
|
|
|
Hemato-oncology / Original Article
The role of platelet function analyzer-200 in predicting perioperative bleeding risk
Eun Sang Yu, Min Ji Jeon, Ka-Won Kang, Byung-Hyun Lee, Eun Joo Kang, Yong Park, Se Ryeon Lee, Hwa Jung Sung, Chul Won Choi, Byung Soo Kim, Dae Sik Kim
Korean J Intern Med. 2020;35(5):1199-1209. Published online February 6, 2020
Background/Aims: Various preoperative screening tests, such as platelet count, prothrombin time, activated partial thromboplastin time, and bleeding time, have been widely used to evaluate the risk of bleeding during surgery. Use of platelet function analyzer (PFA)-100/200 for assessing platelet fun..
|
|
|
Hemato-oncology / Original Article
Immature platelet fraction based diagnostic predictive scoring model for immune thrombocytopenia
Min Ji Jeon, Eun Sang Yu, Ka-Won Kang, Byung-Hyun Lee, Yong Park, Se Ryeon Lee, Hwa Jung Sung, Soo Yong Yoon, Chul Won Choi, Byung Soo Kim, Dae Sik Kim
Korean J Intern Med. 2020;35(4):970-978. Published online April 10, 2020
Background/Aims: The diagnosis of immune thrombocytopenia (ITP) is based on clinical manifestations and there is no gold standard. Thus, even hematologic malignancy is sometimes misdiagnosed as ITP and adequate treatment is delayed. Therefore, novel diagnostic parameters are needed to distinguish IT..
|
|
|
Review
Recent insights regarding the molecular basis of myeloproliferative neoplasms
Mi-Ae Jang, Chul Won Choi
Korean J Intern Med. 2020;35(1):1-11. Published online November 29, 2019
Myeloproliferative neoplasms (MPNs) are a heterogeneous group of clonal disorders characterized by the overproduction of mature blood cells that have an increased risk of thrombosis and progression to acute myeloid leukemia. Next-generation sequencing studies have provided key insights regarding the..
|
|
|
Hemato-oncology / Original Article
Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
Se Ryeon Lee, Hojoon Choi, Byung Hyun Lee, Ka-Won Kang, Eun Sang Yu, Dae Sik Kim, Yong Park, Chul Won Choi, Byung Soo Kim, Hwa Jung Sung
Korean J Intern Med. 2019;34(6):1333-1346. Published online October 26, 2018
Background/Aims: Bortezomib plus melphalan-prednisone (VMP) is a standard treatment for multiple myeloma, particularly for patients who are ineligible for high-dose therapy. However, early discontinuation or treatment modification is often needed owing to adverse events. The aim of this study was to..
|
|
|
Letter to the editor
Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib
Dae Sik Kim, Sunki Lee, Chul Won Choi
Korean J Intern Med. 2018;33(3):642-644. Published online June 28, 2017
|
|
|
Hemato-oncology / Original Article
Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications
Junghoon Shin, Youngil Koh, Jeonghwan Youk, Miso Kim, Byung Soo Kim, Chul Won Choi, Hwa Jung Sung, Yong Park, Sung-Soo Yoon, Inho Kim
Korean J Intern Med. 2017;32(4):722-730. Published online June 26, 2017
Background/Aims: Although multiple myeloma (MM) is typically a disease of the elderly, a certain subset of extremely young patients exists. It is necessary to establish clinicopathological characteristics for this population.
Methods: We reviewed the medical records of MM patients whose age was 40 ..
|
|
|
Hemato-oncology / Original Article
Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma
Dae Sik Kim, Eun Sang Yu, Ka-Won Kang, Se Ryeon Lee, Yong Park, Hwa Jung Sung, Chul Won Choi, Byung Soo Kim
Korean J Intern Med. 2017;32(4):711-721. Published online November 4, 2016
Background/Aims: The aims of this study were to identify the value of inflammatory markers as pretreatment prognostic factors for patients with multiple myeloma (MM) and to estimate the value of a prognostic index including these markers at diagnosis.
Methods: A total of 273 newly diagnosed MM pati..
|
|
|
Hemato-oncology / Original Article
Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells
Dae Sik Kim, Yoo Jin Na, Myoung Hee Kang, Soo-Young Yoon, Chul Won Choi
Korean J Intern Med. 2016;31(2):357-366. Published online February 15, 2016
Background/Aims: The treatment of chronic myeloid leukemia (CML) has achieved impressive success since the development of the Bcr-Abl tyrosine kinase inhibitor, imatinib mesylate. Nevertheless, resistance to imatinib has been observed, and a substantial number of patients need alternative treatment ..
|
|
|
Hemato-oncology / Review
Guidelines for the management of myeloproliferative neoplasms
Chul Won Choi, Soo-Mee Bang, Seongsoo Jang, Chul Won Jung, Hee-Jin Kim, Ho Young Kim, Soo-Jeong Kim, Yeo-Kyeoung Kim, Jinny Park, Jong-Ho Won
Korean J Intern Med. 2015;30(6):771-788. Published online October 30, 2015
Polycythemia vera, essential thrombocythemia, and primary myelofibrosis are collectively known as ‘Philadelphia-negative classical myeloproliferative neoplasms (MPNs).’ The discovery of new genetic aberrations such as Janus kinase 2 (JAK2) have enhanced our understanding of the pathophysio..
|
|
|
Hemato-oncology / Original Article
Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer’s ring: nationwide Korean study
Seong Jun Lee, Cheol Won Suh, Soon Il Lee, Won Seog Kim, Won Sik Lee, Hyo Jung Kim, Chul Won Choi, Jin Seok Kim, Jin Seok Kim, Ho-Jin Shin, Ho-Jin Shin, The Consortium for Improving Survival of Lymphoma , The Consortium for Improving Survival of Lymphoma
Korean J Intern Med. 2014;29(3):352-360. Published online April 29, 2014
Background/Aims: In Asia, the incidence of non-Hodgkin lymphoma (NHL) has increased in recent decades. Waldeyer’s ring (WR) is the most common site of NHL involving the head and neck. In this study, the pathological distribution of WR-NHL and its clinical features were analyzed retrospectiv..
|
|
|
Case Report
Unusual Presentation of Thymic Carcinoma : Hypertrophic Osteoarthropathy
Seok Jin Kim, Jae Hong Seo, Chul won Choi, Eung Seok Lee, Bo Kyoung Seo, and Jun Suk Kim
Korean J Intern Med. 2003;18(2):125-128. Published online June 1, 2003
|
|
|
